|
Iovance Biotherapeutics, Inc. (IOVA) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Iovance Biotherapeutics, Inc. (IOVA) Bundle
Möchten Sie den inneren Wert von Iovance Biotherapeutics, Inc. beurteilen? Unser (IOVA) DCF-Taschenrechner integriert reale Daten mit umfassenden Anpassungsfunktionen, sodass Sie Ihre Prognosen verfeinern und fundiertere Investitionsentscheidungen treffen können.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | 1.2 | 164.1 | 205.1 | 256.4 | 320.4 | 400.6 | 500.7 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 13698.99 | 25 | 25 | 25 | 25 | 25 |
| EBITDA | -250.9 | -328.3 | -374.8 | -427.4 | -395.3 | 41.0 | 51.3 | 64.1 | 80.1 | 100.1 |
| EBITDA, % | 100 | 100 | 100 | -35948.86 | -240.92 | 20 | 20 | 20 | 20 | 20 |
| Depreciation | 8.7 | 14.0 | 21.1 | 33.1 | .0 | 164.1 | 205.1 | 256.4 | 320.4 | 400.6 |
| Depreciation, % | 100 | 100 | 100 | 2786.12 | 0 | 80 | 80 | 80 | 80 | 80 |
| EBIT | -259.6 | -342.3 | -395.9 | -460.6 | -395.3 | 41.0 | 51.3 | 64.1 | 80.1 | 100.1 |
| EBIT, % | 100 | 100 | 100 | -38734.99 | -240.92 | 20 | 20 | 20 | 20 | 20 |
| Total Cash | 629.4 | 596.0 | 471.8 | 279.9 | 323.8 | 205.1 | 256.4 | 320.4 | 400.6 | 500.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .2 | 69.3 | 145.6 | 182.0 | 227.5 | 284.4 | 355.5 |
| Account Receivables, % | 100 | 100 | 100 | 12.7 | 42.26 | 70.99 | 70.99 | 70.99 | 70.99 | 70.99 |
| Inventories | .0 | .0 | .0 | 10.4 | 51.5 | 177.0 | 221.2 | 276.5 | 345.6 | 432.0 |
| Inventories, % | 100 | 100 | 100 | 872.33 | 31.4 | 86.28 | 86.28 | 86.28 | 86.28 | 86.28 |
| Accounts Payable | 13.5 | 27.4 | 26.6 | 33.1 | 27.5 | 170.9 | 213.7 | 267.1 | 333.9 | 417.4 |
| Accounts Payable, % | 100 | 100 | 100 | 2785.79 | 16.77 | 83.35 | 83.35 | 83.35 | 83.35 | 83.35 |
| Capital Expenditure | -46.8 | -37.6 | -20.4 | -22.3 | -11.1 | -43.8 | -54.7 | -68.4 | -85.5 | -106.9 |
| Capital Expenditure, % | 100 | 100 | 100 | -1874.68 | -6.75 | -21.35 | -21.35 | -21.35 | -21.35 | -21.35 |
| Tax Rate, % | 0.75412 | 0.75412 | 0.75412 | 0.75412 | 0.75412 | 0.75412 | 0.75412 | 0.75412 | 0.75412 | 0.75412 |
| EBITAT | -257.2 | -327.8 | -389.9 | -457.0 | -392.3 | 40.3 | 50.4 | 63.0 | 78.8 | 98.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -281.8 | -337.6 | -390.0 | -450.1 | -519.3 | 102.4 | 162.9 | 203.6 | 254.5 | 318.1 |
| WACC, % | 8.22 | 8.21 | 8.22 | 8.22 | 8.22 | 8.22 | 8.22 | 8.22 | 8.22 | 8.22 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 794.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 325 | |||||||||
| Terminal Value | 5,219 | |||||||||
| Present Terminal Value | 3,516 | |||||||||
| Enterprise Value | 4,311 | |||||||||
| Net Debt | -58 | |||||||||
| Equity Value | 4,369 | |||||||||
| Diluted Shares Outstanding, MM | 290 | |||||||||
| Equity Value Per Share | 15.07 |
What You Will Receive
- Pre-Filled Financial Model: Iovance Biotherapeutics' actual data provides an accurate DCF valuation.
- Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Automatic updates allow you to view results instantly as you make adjustments.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
- Flexible and Reusable: Designed for adaptability, enabling repeated application for in-depth forecasts.
Key Features
- 🔍 Real-Life IOVA Financials: Pre-filled historical and projected data for Iovance Biotherapeutics, Inc. (IOVA).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Iovance’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Iovance’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download: Obtain the pre-built Excel file containing Iovance Biotherapeutics, Inc. (IOVA) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC as needed.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and analyze results immediately.
- Make Decisions: Leverage the valuation outcomes to inform your investment approach.
Why Choose This Calculator for Iovance Biotherapeutics, Inc. (IOVA)?
- User-Friendly Interface: Perfectly crafted for both novice and seasoned users.
- Customizable Inputs: Adjust parameters easily to tailor your financial analysis.
- Real-Time Feedback: Instantly observe changes in Iovance's valuation as you modify inputs.
- Pre-Configured Data: Comes with Iovance’s actual financial statistics for swift evaluations.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Investors: Evaluate Iovance Biotherapeutics’ (IOVA) market potential before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess financial forecasts.
- Startup Founders: Understand the valuation processes of innovative biotech firms like Iovance.
- Consultants: Create comprehensive valuation reports for biotech clients.
- Students and Educators: Utilize current data to learn and teach valuation strategies in the biotech sector.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Iovance Biotherapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Iovance Biotherapeutics, Inc. (IOVA).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.